COMP Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products (COMP) is the European Medicines Agency's scientific committee responsible for the scientific evaluation of applications for orphan designation. During its development, a medicinal product can already receive the orphan drug designation which then has to be confirmed at the time of the marketing authorisation.
The Committee for Orphan Medicinal Products consists of scientific experts from all Member States of the EEA including patient representatives and healthcare professionals. For further information on the Committee for Orphan Medicinal Products please visit the European Medicines Agency's website. A list of all substances and medicinal products with an orphan drug designation can be found in the European Commission's Union Register of orphan medicinal products for human use.
The German COMP delegate is Dr. Frauke Naumann-Winter.